崔奥媛
Aoyuan Cui, Ph.D.
Associate Professor of Shanghai Institute of Nutrition and Health
CAS Key Laboratory of Nutrition, Metabolism and Food Safety
Chinese Academy of Sciences
Phone: 021-5492-0924
E-mail: aycui@sinh.ac.cn
Education Background & Academic Experience:
Dr. Aoyuan Cui obtained her Bachelor’s degree in Biotechnology from School of Life Science at Lanzhou University in 2014. She received her PhD degree from Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai in 2020. Then she did her postdoctoral training at Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences. She joined the faculty of Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences in 2022.
Research Interests:
She has been engaged in the research of the molecular mechanism of obesity and diabetes. Recent studies have discovered the role of glucose signals in the regulation of thermogenesis and metabolic homeostasis during the browning of adipose tissues. She is also interested in discovering the pathogenesis and therapeutic strategies of nonalcoholic fatty liver diseases and hepatitis.
Grants and Funding
Her research were funded by Project of National Natural Science Foundation of China (国家自然科学基金委面上项目、青年项目) and the Project of China Postdoctoral Science Foundation (中国博士后科学基金会面上项目).
Personal interests and hobbies:
Her Myers-Briggs Type Indicator (MBTI) is Introverted, iNtuitive, Feeling and Judging (INFJ). She likes running, hiking and playing ping pong and enjoys reading and delicious food in her spare time.
Peer-reviewed Publications:
1. Cui A#, Xue Y#, Su W#, Lin J, Liu Y, Cai G, Wan Q, Jiang Y, Ding D, Zheng Z, Wei S, Li W, Shen J, Wen J, Huang M, Zhao J, Zhang X, Zhao Y, Li H, Ying H, Zhang H, Bi Y, Chen Y, Xu A, Xu Y*, Li Y*. Glucose regulation of adipose tissue browning by CBP/p300 and HDAC3-mediated reversible acetylation of CREBZF. Proceedings of the National Academy of Sciences. 2024 (in press)
2. Ma F, Liu Y, Hu Z, Xue Y, Liu Z, Cai G, Su W, Zheng Z, Fang Z, Yan X, Ding D, Sun X, Jiang Y, Wei S, Li W, Zhao J, Zhang H, Li H, Xiao D, Zhang C, Ying H, Qin J, Gao X, Dai X, Fu W, Xu Y*, Li Y*, Cui A*. Intrahepatic osteopontin signaling by CREBZF defines a checkpoint for steatosis-to-NASH progression. Hepatology. 2023, 78(5):1492-1505
3. Xue Y#, Cui A#, Wei S, Ma F, Liu Z, Fang X, Huo S, Sun X, Li W, Hu Z, Liu Y, Cai G, Su W, Zhao J, Yan X, Gao C, Wen J, Zhang H, Li H, Liu Y, Lin X, Xu Y, Fu W*, Fang J*, Li Y*. Proline hydroxylation of CREB-regulated transcriptional coactivator 2 controls hepatic glucose metabolism. Proceedings of the National Academy of Sciences. 2023, 120(23):e2219419120
4. Liu Y#, Su W#, Liu Z#, Hu Z, Shen J, Zheng Z, Ding D, Huang W, Li W, Cai G, Wei S, Li N, Fang X, Li H, Qin J, Zhang H, Xiao Y, Bi Y, Cui A*, Zhang C*, Li Y*. Macrophage CREBZF orchestrates inflammatory response to potentiate insulin resistance and type 2 diabetes. Advanced Science. 2024, e2306685
5. Ren R, He Y, Ding D, Cui A, Bao H, Ma J, Hou X, Li Y, Feng D, Li X, Liangpunsakul S, Gao B*, Wang H*. Aging exaggerates acute-on-chronic alcohol-induced liver injury in mice and humans by inhibiting neutrophilic Sirtuin 1-C/EBPα-miRNA-223 axis. Hepatology. 2022, 75(3):646-660
6. Cui A, Ding D, Li Y*. Regulation of hepatic metabolism and cell growth by the ATF/CREB family of transcription factors. Diabetes. 2021, 70(3):653-664
7. Hu Z#, Han Y#, Liu Y, Zhao Z, Ma F, Cui A, Zhang F, Liu Z, Xue Y, Bai J, Wu H, Bian H, Chin YE, Yu Y, Meng Z, Wang H, Liu Y, Fan J, Gao X, Chen Y, Li Y*. CREBZF as a key regulator of STAT3 pathway in the control of liver regeneration in mice. Hepatology. 2020, 71(4):1421-1436
8. Cui A#, Li J#, Ji S#, Ma F, Wang G, Xue Y, Liu Z, Gao J, Han J, Tai P, Wang T, Chen J, Ma X*, Li Y*. The effects of B1344, a novel fibroblast growth factor 21 analog, on nonalcoholic steatohepatitis in nonhuman primates. Diabetes. 2020, 69(8):1611-1623
Highlighted by Commentary: Kleinert M, Muller TD. A new FGF21 analog for the treatment of fatty liver disease. Diabetes. 2020, 69(8):1605-1607
9. Zhang F, Hu Z, Li G, Huo S, Ma F, Cui A, Xue Y, Han Y, Gong Q, Gao J, Bian H, Meng Z, Wu H, Long G, Tan Y, Zhang Y, Lin X, Gao X, Xu A, Li Y*. Hepatic CREBZF couples insulin to lipogenesis by inhibiting Insig activity and contributes to hepatic steatosis in diet-induced insulin-resistant mice. Hepatology. 2018, 68(4):1361-1375
10. Cui A, Hu Z, Han Y, Yang Y, Li Y*. Optimized analysis of In vivo and in vitro hepatic steatosis. Journal of Visualized Experiments. 2017, e55178
11. Gong Q, Hu Z, Zhang F, Cui A, Chen X, Jiang H, Gao J, Chen X, Han Y, Liang Q, Ye D, Shi L, Chin YE, Wang Y, Xiao H, Guo F, Liu Y, Zang M, Xu A, Li Y*. Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1. Hepatology. 2016, 64(2):425-438
12. Chen X, Zhang F, Gong Q, Cui A, Zhuo S, Hu Z, Han Y, Gao J, Sun Y, Liu Z, Yang Z, Le Y, Gao X, Dong LQ, Gao X, Li Y*. Hepatic ATF6 increases fatty acid oxidation to attenuate hepatic steatosis in mice through peroxisome proliferator-activated receptor alpha. Diabetes. 2016, 65(7):1904-1915
